A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT04104776
Phase: Phase 1|Phase 2
Trial Summary: First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Constellation Pharmaceuticals
Acronym:

Pin It on Pinterest